Craig Scoville, MD
Rheumatology · Idaho Falls, IDNPI 1194818997
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $19,798 of the $26,375 with a category attached, or 75.1%. 31 manufacturers reported payments, led by Amgen at 25.5% of the total. Reporting peaked in 2020 at $7,123 and has fallen 52.0% since, to $3,419 in 2025. Among rheumatology clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,325 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- Regeneron$6K
- AbbVie$2K
- Novartis$2K
- UCB, Inc.$1K
- GSK$1K
- plus $7K from 25 others
Across 174 payments — averaging $4185.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$200K
- Astrazeneca UK Limited$147K
- UCB SA$101K
- Pfizer$89K
- Novartis$78K
- AbbVie$52K
- plus $61K from 4 others
What the payments were for
- Consulting fees$5,04019%
- Travel & lodging$7773%
- Food & beverage$19,79875%
- Education$7593%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 514 | $6,725 |
| Regeneron | 14 | $6,227 |
| AbbVie | 143 | $2,454 |
| Novartis | 85 | $1,699 |
| UCB, Inc. | 81 | $1,445 |
| GSK | 82 | $1,049 |
| Lilly USA, LLC | 62 | $1,030 |
| AstraZeneca(2 entities) | 36 | $807 |
| Mallinckrodt Hospital Products Inc. | 41 | $804 |
| E.r. Squibb & Sons, L.L.C. | 52 | $771 |
| Johnson & Johnson | 30 | $758 |
| Pfizer | 74 | $607 |
| Genentech USA, Inc. | 16 | $390 |
| Bristol Myers Squibb | 34 | $273 |
| Regeneron Healthcare Solutions, Inc. | 8 | $207 |
| Fresenius Kabi USA, LLC | 8 | $143 |
| Sobi, Inc | 4 | $128 |
| ANI Pharmaceuticals, Inc. | 5 | $115 |
| Organon | 5 | $96 |
| Janssen Scientific Affairs, LLC | 1 | $88 |
| Radius Health, Inc. | 5 | $86 |
| Sanofi | 5 | $83 |
| Boehringer Ingelheim | 3 | $61 |
| Sandoz | 3 | $59 |
| Boston Scientific | 3 | $54 |
| Mallinckrodt Enterprises LLC | 3 | $53 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $51 |
| Ultragenyx Pharmaceutical Inc. | 2 | $38 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $36 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,375 in reported general payments places this provider in the 90th percentile of 28 rheumatology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 13 | $118,552 |
| Xeljanz XrTofacitinib Citrate | 13 | $73,451 |
| Celecoxib | 325 | $21,941 |
| Hydroxychloroquine Sulfate | 530 | $11,572 |
| Leflunomide | 65 | $7,736 |
| Cevimeline Hcl | 22 | $5,190 |
| MethotrexateMethotrexate Sodium | 158 | $2,765 |
| Colchicine | 43 | $2,720 |
| Duloxetine Hcl | 87 | $1,835 |
| Omeprazole | 214 | $1,710 |
| Mycophenolate Mofetil | 22 | $1,543 |
| Pilocarpine Hcl | 26 | $1,294 |
| Prednisone | 248 | $1,292 |
| Azathioprine | 52 | $1,289 |
| Gabapentin | 61 | $1,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Scilex Pharmaceuticals Inc.Colchicine | $18 | $2,72043 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 28 rheumatology providers in Idaho.
Other rheumatology in Idaho Falls
- Dustin DinningCoeur D Alene$311K
- William KnibbeBoise$164K
- Christopher GibsonAshton$18K
- James LovelessBoise$12K
- Peggy Ann RuppBoise$11K
- Craig WiesenhutterCoeur D Alene$7K
- Sean McMillanTwin Falls$4K
- Francis NardellaMeridian$3K
- Linda SakaiCoeur D Alene$3K
- Chara SolichMeridian$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.